All Stories

  1. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Article • Journal of Clinical Oncology, January 2020, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  2. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma

    Article • Clinical Pharmacokinetics, May 2019, Springer Science + Business Media

    Dr Mohamed Bouattour

  3. Management of immune-related adverse events resulting from immune checkpoint blockade

    Article • Expert Review of Anticancer Therapy, December 2018, Taylor & Francis

    Dr Mohamed Bouattour

  4. Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005

    Article • HepatoBiliary Surgery and Nutrition, September 2018, AME Publishing Company

    Dr Mohamed Bouattour

  5. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

    Article • Hepatology, May 2018, Wiley

    Dr Mohamed Bouattour

  6. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?

    Article • Journal of Hepatology, May 2018, Elsevier

    Dr Mohamed Bouattour

  7. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

    Article • Hepatology, February 2018, Wiley

    Dr Mohamed Bouattour

  8. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

    Article • The Lancet Oncology, October 2017, Elsevier

    Dr Mohamed Bouattour

  9. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

    Article • ESMO Open, October 2017, BMJ

    Dr Mohamed Bouattour

  10. LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial

    Article • Annals of Oncology, June 2017, Oxford University Press (OUP)

    Dr Mohamed Bouattour

  11. Carcinome hépatocellulaire : nouveaux concepts, nouvelles molécules et nouvelles approches

    Article • ONCOLOGIE, June 2017, Lavoisier

    Dr Mohamed Bouattour

  12. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

    Article • Current Controlled Trials in Cardiovascular Medicine, November 2016, Springer Science + Business Media

    Dr Mohamed Bouattour

  13. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study

    Article • International Journal of Nanomedicine, November 2016, Dove Medical Press

    Dr Mohamed Bouattour

  14. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia

    Article • Medicine, November 2015, Wolters Kluwer Health

    Dr Mohamed Bouattour

  15. Abstract 221: Ex vivo cultures of freshly explanted tumors: a potent translational approach for screening novel targeted agents

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  16. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

    Article • Journal of Clinical Oncology, August 2015, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  17. Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma

    Article • Medicine, July 2015, Wolters Kluwer Health

    Dr Mohamed Bouattour

  18. Reply to M. Bouattour et al

    Article • Journal of Clinical Oncology, June 2015, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  19. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Mohamed Bouattour

  20. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Mohamed Bouattour

  21. Abstract 3484: Ex-vivo cultures of freshly explanted tumor specimens (TIPCAN®), a potent translational approach for screening novel targeted agents

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  22. Molecular Targeted Drugs under Investigation in Hepatocellular Carcinoma

    Article • September 2014, Bentham Science Publishers

    Dr Mohamed Bouattour

  23. The Sorafenib for Hepatocellular Carcinoma (HCC) in Adjuvant Setting: The End of the Story was Already Written?

    Article • Gastroenterology & Hepatology Open Access, August 2014, MedCrave Group LLC

    Dr Mohamed Bouattour

  24. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

    Article • Investigational New Drugs, April 2014, Springer Science + Business Media

    Dr Mohamed Bouattour

  25. P998 BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Mohamed Bouattour

  26. Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

    Article • The Oncologist, March 2014, Alphamed Press

    Dr Mohamed Bouattour

  27. Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact

    Article • Journal of Vascular and Interventional Radiology, November 2013, Elsevier

    Dr Mohamed Bouattour

  28. Abstract C268: MET-inhibition using SU11274 and HER-inhibitions with lapatinib impair proliferation, motility and invasion in hepatocellular carcinoma (HCC) and exhibits an increased efficacy un sorafenib-tolerant model.

    Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  29. Biomarqueurs prédictifs d’efficacité

    Article • January 2013, Springer Science + Business Media

    Dr Mohamed Bouattour

  30. Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus

    Article • Pancreatology, November 2012, Elsevier

    Dr Mohamed Bouattour

  31. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib

    Article • Targeted Oncology, May 2012, Springer Science + Business Media

    Dr Mohamed Bouattour

  32. Thérapies ciblées dans le carcinome hépatocellulaire: indications et perspectives

    Article • ONCOLOGIE, March 2012, Lavoisier

    Dr Mohamed Bouattour

  33. Enjeux et spécificités de l’évaluation radiologique des tumeurs neuroendocrines pancréatiques traitées par les thérapies ciblées

    Article • Cancéro digest, January 2012, INIST-CNRS

    Dr Mohamed Bouattour

  34. Prospective evaluation of the management of hepatocellular carcinoma in the elderly

    Article • Digestive and Liver Disease, December 2011, Elsevier

    Dr Mohamed Bouattour

  35. Abstract B175: TGF- -RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.

    Article • Molecular Cancer Therapeutics, November 2011, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  36. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

    Article • Journal of Hepatology, May 2011, Elsevier

    Dr Mohamed Bouattour

  37. Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Mohamed Bouattour

  38. Novel molecular therapies in hepatocellular carcinoma

    Article • Liver International, January 2011, Wiley

    Dr Mohamed Bouattour

  39. Prise en charge des tumeurs primitives du foie et des voies biliaires

    Article • January 2011, Springer Science + Business Media

    Dr Mohamed Bouattour

  40. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

    Article • European Journal of Gastroenterology & Hepatology, September 2010, Wolters Kluwer Health

    Dr Mohamed Bouattour

  41. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

    Article • Expert Opinion on Drug Metabolism & Toxicology, July 2010, Informa Healthcare

    Dr Mohamed Bouattour

  42. Thérapies ciblées dans le carcinome hépatocellulaire

    Article • La Presse Médicale, July 2010, Elsevier

    Dr Mohamed Bouattour

  43. Les nouveaux antiangiogéniques : état de la recherche

    Article • Cancéro digest, January 2010, INIST-CNRS

    Dr Mohamed Bouattour

  44. Les antiangiogéniques dans le carcinome hépatocellulaire en dix questions

    Article • Cancéro digest, January 2010, INIST-CNRS

    Dr Mohamed Bouattour

  45. Sunitinib in Hepatocellular Carcinoma: Redefining Appropriate Dosing, Schedule, and Activity End Points

    Article • Journal of Clinical Oncology, December 2009, American Society of Clinical Oncology (ASCO)

    Dr Mohamed Bouattour

  46. Feeding Soybean Oil to Dairy Goats Increases Conjugated Linoleic Acid in Milk

    Article • Journal of Dairy Science, June 2008, American Dairy Science Association

    Dr Mohamed Bouattour

  47. Atteinte palpébrale au cours d'un syndrome de Löfgren

    Article • La Revue de Médecine Interne, June 2003, Elsevier

    Dr Mohamed Bouattour